Mild Alzheimer's Disease Clinical Trial
Official title:
WeArable Neuromodulation DeVice for the TrEatment of Alzheimer's Disease
This is a double- blind, randomized controlled trial with an open label extension designed to evaluate the safety and potential efficacy of a non-invasive brainstem neuromodulation device for treating symptoms associated with Alzheimer's disease (AD).
Up to 45 participants will first enter the double-blind, randomized controlled trial during which they will self-administer treatments twice daily in the home setting over 24 weeks with one of two investigational treatment modes. Participants who complete the randomized controlled trial will then enter the open label extension where all participants will self-administer twice-daily treatments over 24 weeks using the same investigational treatment mode that was reported to show benefit in a previous clinical trial in another neurodegenerative disease. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT00243451 -
Early Detection of Mild Cognitive Impairment in Individual Patients
|
N/A | |
| Recruiting |
NCT05872243 -
pBFS Guided rTMS Treating Mild Alzheimer's Disease(AD)
|
N/A | |
| Recruiting |
NCT05417555 -
Low Intensity Focused Ultrasound for Mild Cognitive Impairment and Mild Alzheimer's Disease
|
N/A | |
| Terminated |
NCT01482013 -
Safety Study of HPP854 in Subjects With Mild Cognitive Impairment or a Diagnosis of Mild Alzheimer's Disease
|
Phase 1 | |
| Completed |
NCT03186989 -
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of IONIS-MAPTRx in Patients With Mild Alzheimer's Disease
|
Phase 1/Phase 2 | |
| Not yet recruiting |
NCT03752294 -
A Novel Therapeutic Target for Alzheimer's Disease in Men and Women 50-85 Years of Age.
|
Phase 1 | |
| Completed |
NCT01013610 -
An Escalating Dose Study to Evaluate the Safety, Tolerability and Pharmacokinetics of LNK 754 in Elderly Volunteers and in Subjects With Mild Alzheimer's Disease
|
Phase 1 | |
| Recruiting |
NCT06058234 -
Medicare Anti-Aβ mAb Coverage With Evidence Development (CED) Study
|
||
| Active, not recruiting |
NCT03234686 -
Deferiprone to Delay Dementia (The 3D Study)
|
Phase 2 | |
| Completed |
NCT05233774 -
Lomecel-B Effects on Alzheimer's Disease
|
Phase 2 | |
| Terminated |
NCT00582855 -
Effect of AQW051 in Patients With Memory Impairment
|
Phase 2 | |
| Completed |
NCT01061489 -
Sensory-cognitive and Physical Fitness Training in Mild Cognitive Impairment
|
N/A | |
| Completed |
NCT01548287 -
A Study of the Safety and Tolerability of AZD5213 Effect on Sleep for Patients With Alzheimer's/Cognitive Impairment
|
Phase 2 | |
| Terminated |
NCT00706186 -
Safety and Feasibility of Sodium Oxybate in Mild Alzheimer's Disease Patients
|
Phase 4 |